tradmap

PLUR Pluri Inc.

$2.13 -8.19%

Healthcare · Biological Products, (No Diagnostic Substances)

Pluri Inc. (PLUR) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $23 million. Shares last traded at $2.13, 70.0% below their 52-week high. Over the past year the stock is down 49.5%. PLUR trades at a price-to-earnings ratio of 0.99, below the Biological Products, (No Diagnostic Substances) median of 22.74. Net profit margin is 1740.3%, above the peer median of 6.3%. Revenue grew 309.8% year over year.

Market Cap
$23M
Shares Out
10.8M
EPS (TTM)
$-6.47
P/E Ratio
0.99
P/S Ratio
17.20
P/B Ratio
Dividend / Share
Dividend Yield
52-Week High
$7.09
52-Week Low
$2.12
Volume
677
Avg Vol (3m)
362.413

Performance

1W
-11.25%
1M
-37.72%
3M
-32.38%
6M
-55.63%
YTD
-30.16%
1Y
-49.53%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
28.85
SMA (50)
$3.16
SMA (200)
$4.02
Price vs SMA50
-32.67%
Price vs SMA200
-46.98%
ATR (14)
$0.16

Financials

Revenue
$1M
Net Income
$23M
Gross Margin
49.0%
Operating Margin
-1659.9%
Net Margin
1740.3%
Return on Equity
-125.0%
Return on Assets
89.2%
Current Ratio
0.33
Debt / Equity
Revenue Growth (YoY)
+309.8%

Latest reported annual period ending 2025-06-30 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q3 2026 $-1.90 2026-05-14
Q2 2026 $-1.36 2026-02-12
Q1 2026 $-0.65 2025-11-12
FY 2025 $-3.56 2025-09-17
Q3 2026 $-2.56 2026-05-14
Q2 2026 $-1.61 2026-02-12

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

PLUR vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/E vs peers
0.99 / 22.74 med
-96% discount
P/S vs peers
17.20 / 5.21 med
+230% premium
Net margin vs peers
1740.3% / 6.3% med
above median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.